tbuckley/cabot-search huggingface dataset:
I Solemnly Share
Authors: Rahael Gupta
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
First Modified-Risk Combusted Cigarettes Are Authorized
Authors: Rebecca Voelker
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Gut microbiome and health: mechanistic insights
Authors: Willem M de Vos, Herbert Tilg, Matthias Van Hul, Patrice D Cani
Journal: Gut (2022)

The gut microbiota is now considered as one of the key elements contributing to the regulation of host health. Virtually all our body sites are colonised by microbes suggesting different types of crosstalk with our organs. Because of the development of molecular tools and techniques (ie, metagenomic, metabolomic, lipidomic, metatranscriptomic), the complex interactions occurring between the host and the different microorganisms are progressively being deciphered. Nowadays, gut microbiota deviations are linked with many diseases including obesity, type 2 diabetes, hepatic steatosis, intestinal bowel diseases (IBDs) and several types of cancer. Thus, suggesting that various pathways involved in immunity, energy, lipid and glucose metabolism are affected. In this review, specific attention is given to provide a critical evaluation of the current understanding in this field. Numerous molecular mechanisms explaining how gut bacteria might be causally linked with the protection or the onset of diseases are discussed. We examine well-established metabolites (ie, short-chain fatty acids, bile acids, trimethylamine N-oxide) and extend this to more recently identified molecular actors (ie, endocannabinoids, bioactive lipids, phenolic-derived compounds, advanced glycation end products and enterosynes) and their specific receptors such as peroxisome proliferator-activated receptor alpha (PPARα) and gamma (PPARγ), aryl hydrocarbon receptor (AhR), and G protein-coupled receptors (ie, GPR41, GPR43, GPR119, Takeda G protein-coupled receptor 5). Altogether, understanding the complexity and the molecular aspects linking gut microbes to health will help to set the basis for novel therapies that are already being developed.
Dermatoscopic and clinical features of congenital or congenital-type nail matrix nevi: A multicenter prospective cohort study by the International Dermoscopy Society
Authors: Félix Pham, Amélie Boespflug, Gérard Duru, Alice Phan, Nicolas Poulalhon, Laura Weiler, Masaru Tanaka, Aimilios Lallas, Dai Ogata, Anne Céline Davaine, Philippe Bahadoran, Xavier Balguerie, Grażyna Kamińska-Winciorek, Isabelle Tromme, Osvaldo Correia, Moon-Bum Kim, Ashfaq A. Marghoob, None Linda Martin, Pascale Guitera, Mariame Meziane, Juliette Miquel, Je-Ho Mun, Giuseppe Argenziano, Didier Bessis, Johnny Bourke, Zeljko Mijuskovic, Christine Chiaverini, Cloé Corven-Benoit, Catherine Droitcourt, François Skowron, Myriam Marque, Iris Zalaudek, Cliff Rosendahl, David Moreno-Ramirez, Pierre Vabres, Holger Haenssle, Josep Malvehy, Susana Puig, Caroline Robert, Thomas R. Schopf, Alon Scope, Stéphane Dalle, Luc Thomas
Journal: Journal of the American Academy of Dermatology (2022)
Effect of Patient Portal Messaging Before Mailing Fecal Immunochemical Test Kit on Colorectal Cancer Screening Rates
Authors: Gregory Goshgarian, Camille Sorourdi, Folasade P. May, Sitaram Vangala, Sarah Meshkat, Lily Roh, Maria A. Han, Daniel M. Croymans
Journal: JAMA Network Open (2022)

Colorectal cancer (CRC) screening reduces CRC mortality; however, screening rates remain well below the national benchmark of 80%.
Maintenance of ATP in Stored Blood by Adenosine and Inosine
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reexamining Risks of Prenatal Cannabis Use—Mounting Evidence and a Call to Action
Authors: Kara R. Skelton, Sara E. Benjamin-Neelon
Journal: JAMA Network Open (2022)

Greg Marchand, MD; Ahmed Taher Masoud, MD; Malini Govindan, MD; Kelly Ware, MS; Alexa King, BS; Stacy Ruther, BS; Giovanna Brazil, BS; Hollie Ulibarri, BS; Julia Parise, BS; Amanda Arroyo, BS; Catherine Coriell, BS; Sydnee Goetz, BS; Amitis Karrys, BS; Katelyn Sainz, MD
Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analysis of a Phase I/II Study
Authors: Anas Younes, John M Burke, Bruce D. Cheson, Catherine Diefenbach, Silvia Ferrari, Uwe H Hahn, Eliza A Hawkes, Cyrus Khan, Izidore S. Lossos, Gerardo Musuraca, Monica Tani, Umberto Vitolo, Sam Lung Sang Yuen, Aparna Raval, Mahesh R. Shivhare, Tina G Nielsen, Gila Sellam, Jeff P. Sharman
Journal: Blood (2019)
接触性胰岛素泵过敏
Journal: British Journal of Dermatology (2022)

Journal Article 接触性胰岛素泵过敏 Get access British Journal of Dermatology, Volume 186, Issue 2, 1 February 2022, Page e108, https://doi.org/10.1111/bjd.20936 Published: 01 February 2022
AMA seeks loan deferment legislation
Journal: JAMA (1990)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Loss of miR-31-5p drives hematopoietic stem cell malignant transformation and restoration eliminates leukemia stem cells in mice
Authors: Biying Zhu, Wenbin Zhong, Xiuye Cao, Guoping Pan, Mengyang Xu, Jie Zheng, Huanzhao Chen, Xiaoqin Feng, Chengwei Luo, Chen Lu, Jie Xiao, Weize Lin, Chaofeng Lai, Mingchuan Li, Xin Du, Qing Yi, Daoguang Yan
Journal: Science Translational Medicine (2022)

Leukemia stem cells (LSCs) propagate leukemia and are responsible for the high frequency of relapse of treated patients. The ability to target LSCs remains elusive, indicating a need to understand the underlying mechanism of LSC formation. Here, we report that miR-31-5p is reduced or undetectable in human LSCs compared to hematopoietic stem progenitor cells (HSPCs). Inhibition of miR-31-5p in HSPCs promotes the expression of its target gene FIH , encoding FIH [factor inhibiting hypoxia-inducing factor 1α (HIF-1α)], to suppress HIF-1α signaling. Increased FIH resulted in a switch from glycolysis to oxidative phosphorylation (OXPHOS) as the predominant mode of energy metabolism and increased the abundance of the oncometabolite fumarate. Increased fumarate promoted the conversion of HSPCs to LSCs and initiated myeloid leukemia-like disease in NOD-Prkdc scid IL2rg tm1 /Bcgen (B-NDG) mice. We further demonstrated that miR-31-5p inhibited long- and short-term hematopoietic stem cells with a high frequency of LSCs. In combination with the chemotherapeutic agent Ara-C (cytosine arabinoside), restoration of miR-31-5p using G7 poly (amidoamine) nanosized dendriplex encapsulating miR-31-5p eliminated LSCs and inhibited acute myeloid leukemia (AML) progression in patient-derived xenograft mouse models. These results demonstrated a mechanism of HSC malignant transformation through altered energy metabolism and provided a potential therapeutic strategy to treat patients with AML.
Histologically resolved small RNA maps in primary focal segmental glomerulosclerosis indicate progressive changes within glomerular and tubulointerstitial regions
Authors: Anna Marie Williams, David M Jensen, Xiaoqing Pan, Pengyuan Liu, Jing Liu, Sean Huls, Kevin R Regner, Kenneth A Iczkowski, Feng Wang, Junhui Li, Alexander J Gallan, Tao Wang, Maria Angeles Baker, Yong Liu, Nava Lalehzari, Mingyu Liang
Journal: Kidney International (2022)
Ipilimumab Combination Dosing: Less is More
Authors: Max Jameson-Lee, Jason J. Luke
Journal: Clinical Cancer Research (2021)

Ipilimumab with and without anti-Programmed Death 1 (PD-1) improved overall survival (OS) in melanoma. Despite this, the optimal dose and therapeutic mechanism of ipilimumab in patients remains unclear. KEYNOTE-029 and other studies suggest that low-dose ipilimumab with anti-PD1 maintains efficacy while decreasing toxicity, emphasizing T-cell trafficking and reinvigoration as likely mechanisms. See related article by Long et al., p. 5280.
Episodic Memory Performance Predicted by the 2bp Deletion in Exon 6 of the “Alpha 7-Like” Nicotinic Receptor Subunit Gene
Authors: Emma L. Dempster, Timothea Toulopoulou, Colm McDonald, Elvira Bramon, Muriel Walshe, Harvey Wickham, Pak C. Sham, Robin M. Murray, David A. Collier
Journal: American Journal of Psychiatry (2006)

Objective: There is evidence of linkage between chromosome 15q14 and the P50 auditory evoked response, a heritable neuropsychological marker associated with increased risk of schizophrenia. Chromosome 15q14 harbors the alpha-7 nicotinic receptor subunit gene (CHRNA7) and a hybrid gene of unknown function (CHRFAM7A). CHRNA7 is involved in memory formation, a core dysfunction in schizophrenia. The authors set out to determine if this locus is associated with memory dysfunction in schizophrenia. Method: A 2bp deletion in exon 6 of CHRFAM7A, which disrupts the hybrid gene and has previously been associated with P50 deficit, was genotyped in 251 individuals from the Maudsley Family Study of schizophrenia. Episodic memory function was assessed using the Wechsler Memory Scale. Results: Significant associations were identified with delayed recall and percentage retained, with the presence of the deletion predicting worse performance. Conclusions: These observations indicate that episodic memory function is a schizophrenia endophenotype and implicate the CHRFAM7A/CHRNA7 locus in modulating its function.
Cardioprotective value of aspirin in primary prevention is greater the lower the blood pressure
Journal: BMJ (2000)

Cardioprotective value of aspirin in primary prevention is greater the lower the blood pressure In primary prevention, middle aged men at increased risk of coronary heart disease seem to benefit more from aspirin when systolic blood pressure is lower.The use of aspirin, often self prescribed, in those who have so far not experienced heart attacks requires careful consideration as only a few episodes will be prevented and even low doses of aspirin may carry an appreciable risk of potentially serious bleeding.The US physicians trial suggested that older men and those with low cholesterol concentrations would benefit most, but the UK thrombosis prevention trial (p 13) does not confirm these suggestions.The UK trial in 5499 men treated over nearly seven years showed that the risk of heart attacks was reduced by about half in those with lower blood pressures whereas there was little if any effect in those with higher pressures.These findings need to be confirmed or refuted, however, before they are taken as firm evidence in clinical practice.No link exists between blood transfusion and sporadic CJD
Large-scale deep multi-layer analysis of Alzheimer’s disease brain reveals strong proteomic disease-related changes not observed at the RNA level
Authors: Erik C. B. Johnson, E. Kathleen Carter, Eric B. Dammer, Duc M. Duong, Ekaterina S. Gerasimov, Yue Liu, Jiaqi Liu, Ranjita Betarbet, Lingyan Ping, Luming Yin, Geidy E. Serrano, Thomas G. Beach, Junmin Peng, Philip L. De Jager, Vahram Haroutunian, Bin Zhang, Chris Gaiteri, David A. Bennett, Marla Gearing, Thomas S. Wingo, Aliza P. Wingo, James J. Lah, Allan I. Levey, Nicholas T. Seyfried
Journal: Nature Neuroscience (2022)

The biological processes that are disrupted in the Alzheimer's disease (AD) brain remain incompletely understood. In this study, we analyzed the proteomes of more than 1,000 brain tissues to reveal new AD-related protein co-expression modules that were highly preserved across cohorts and brain regions. Nearly half of the protein co-expression modules, including modules significantly altered in AD, were not observed in RNA networks from the same cohorts and brain regions, highlighting the proteopathic nature of AD. Two such AD-associated modules unique to the proteomic network included a module related to MAPK signaling and metabolism and a module related to the matrisome. The matrisome module was influenced by the APOE ε4 allele but was not related to the rate of cognitive decline after adjustment for neuropathology. By contrast, the MAPK/metabolism module was strongly associated with the rate of cognitive decline. Disease-associated modules unique to the proteome are sources of promising therapeutic targets and biomarkers for AD.
Exposure to agent orange
Authors: D. J. Fink
Journal: JAMA (1980)

<h3>To the Editor.—</h3> The description by Gilbert Bogen, MD, of "Symptoms in Vietnam Veterans Exposed to Agent Orange" (242:2391, 1979) may be misleading to Vietnam-era veterans and their physicians. Bogen does not describe how his patient population was selected; the degree of exposure claimed by this population to Agent Orange; any documentation (eg, by assay of herbicide levels in fat biopsy specimens) of the exposure to Agent Orange or its systemic absorption and storage; and any comparison of the reported symptoms between the exposed veterans and an age-matched but unexposed population. His report, without reference to a control population, lists the occurrence of several minor and a few more serious mental and physiological symptoms, including a large number of neuropsychiatric and gastrointestinal complaints. These types of problems are not uncommon in young men who seek medical attention for nonspecific and ill-defined complaints. In the patient population described by Bogen, such
Evaluation of Length of Stay, Care Volume, In-Hospital Mortality, and Emergency Readmission Rate Associated With Use of Diagnosis-Related Groups for Internal Resource Allocation in Public Hospitals in Hong Kong
Authors: Yushan Wu, Hong Fung, Ho-Man Shum, Shi Zhao, Eliza Lai-Yi Wong, Ka-Chun Chong, Chi-Tim Hung, Eng-Kiong Yeoh
Journal: JAMA Network Open (2022)

Hong Kong's internal resource allocation system for public inpatient care changed from a global budget system to one based on diagnosis-related groups (DRGs) in 2009 and returned to a global budget system in 2012. Changes in patient and hospital outcomes associated with moving from a DRG-based system to a global budget system for inpatient care have rarely been evaluated.
Total Pericardiectomy for Calcific Constrictive Pericarditis with Extracardiac Intrapericardial Caseating Mass via Median Sternotomy (Holman and Willett’s Approach): A Video Presentation
Authors: Ujjwal K. Chowdhury, Niwin George, Lakshmi Kumari Sankhyan, Shikha Goja, Arindam Choudhury, Shradha Gupta, Vishwas Malik, Niraj Nirmal Pandey
Journal: Clinical Cardiology and Cardiovascular Interventions (2022)

Pericardiectomy is the only accepted curative treatment for chronic constrictive pericarditis and its efficacy in improving symptoms with normalization of hemodynamic in the majority of cases has been established.
Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study)
Authors: Takashi Seto, Kaname Nosaki, Mototsugu Shimokawa, Ryo Toyozawa, Shunichi Sugawara, Hidetoshi Hayashi, Haruyasu Murakami, Terufumi Kato, Seiji Niho, Hideo Saka, Masahide Oki, Hiroshige Yoshioka, Isamu Okamoto, Haruko Daga, Koichi Azuma, Hiroshi Tanaka, Kazumi Nishino, Rie Tohnai, Nobuyuki Yamamoto, Kazuhiko Nakagawa
Journal: Journal for ImmunoTherapy of Cancer (2022)

Background PD-L1 expression on tumor cells is a marker of PD-1/PD-L1 antibody treatment efficacy for advanced non-small cell lung cancer (NSCLC). PD-L1 antibody (atezolizumab) prolongs overall survival (OS) compared with platinum doublet as first-line treatment for NSCLC with high PD-L1 expression. Bevacizumab enhanced cytotoxic agent and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor efficacy in non-squamous (NS)-NSCLC, and PD-1/PD-L1 antibodies in preclinical models. Methods This single-arm phase II study investigated clinical benefits of adding bevacizumab 15 mg/kg to atezolizumab 1200 mg fixed dose in a first-line setting for advanced NS-NSCLC patients with PD-L1 expression ≥50% without EGFR / ALK / ROS1 alterations. Primary endpoint was objective response rate (ORR) assessed by central review committee. Secondary endpoints were progression-free survival (PFS), duration of response (DOR), OS, and safety. Results Of 39 enrolled patients, 33 (84.6%) had stage IV NSCLC and 36 (92.3%) had smoking history. As of March 31, 2020, no patient had a complete response and 25 patients had a partial response (ORR=64.1%, 95% CI 47.18 to 78.80). Twelve-month PFS and OS rates were 54.9% (35.65 to 70.60) and 70.6% (50.53 to 83.74), respectively. The median DOR in 25 responders was 10.4 months (4.63–not reached). The median treatment cycle was 12 (1 to 27). Nineteen patients discontinued study treatment because of disease progression (N=17) or immune-related adverse events (AEs) (N=2) (sclerosing cholangitis or encephalopathy). There were 23 serious AEs in 12 patients, but no grade 4/5 toxicity. Conclusions Atezolizumab with bevacizumab is a potential treatment for NS-NSCLC with high PD-L1 expression. Trial registration number JapicCTI-184038.
Influence of Baseline Total IgE and History of Previous Omalizumab Use on the Impact of Mepolizumab in Reducing Rate of Severe Asthma Exacerbations: Results From the Real-World REALITI-A Study
Authors: Jason Lee, Stephen Pollard, Mark Liu, Florence Schleich, Girolamo Pelaia, Carlos Almonacid, Liam Heaney, Rekha Chaudhuri, Rafael Alfonso-Cristancho, Rupert Jakes, Robert Price, Aoife Maxwell, Peter Howarth
Journal: Journal of Allergy and Clinical Immunology (2022)
942-39 Carcinoid Heart Disease: Correlation of High Serotonin Levels with Valvular Abnormalities Detected by Cardiac Catheterization and Echocardiography
Authors: Paul A. Robiolio, Vera H. Rigolin, John S. Wilson, J. Kevin Harrison, Jerome M. Feldman, Thomas M. Bashore
Journal: Journal of the American College of Cardiology (1995)